Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab’s high-concentration 100.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics studyAdalimumab's high-concentration 100 mg/mL formulation aims to provide an enhanced yet